Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Kaitlyn Sadtler · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2021 · $725,967 — Analysis of Undiagnosed SARS-CoV-2 Infections in the United States Over the past year, our laboratory has led a national serologic survey effort to evaluate the number of undiagnosed SARS-CoV-2 infections. In fall 2020, we discovered almost 17 million undiagnosed infections from the first wave of i…
Thomas Redmond · NATIONAL EYE INSTITUTE · 2021 · $449,897 — Novel coronavirus SARS-CoV-2, originating at the end of 2019 in Wuhan, China, causes the pandemic coronavirus disease COVID-19 that has had a major public health and economic impact in the USA and the rest of the world since then. The disease is quite heterogeneous and targets internal organs with m…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $250,000 — NHP immunized with 10 and 100g of mRNA-1273 encoding the SARS CoV2 had robust neutralizing antibodiy titers following two immunizations. mRNA-1273 induced Th1-biased CD4 T cell responses and low or undetectable Th2 or CD8 T responses. Following an infectious challenge with SARS CoV2 by the intrana…
HANJOON RYU · 2021 · $24,361,759 — Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving …
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $280,000 — To evaluate a large panel of SARS CoV-2 S protein variants for their effect on virus susceptibility to neutralization by a panel of neutralizing antibodies and sera from vaccine recipients…
YOSHIHIRO KAWAOKA · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $4,242,156 — SUMMARY As part of the Pan-Coronavirus Vaccine (PanCoVac) Consortium, the goal of Research Project 1 (RP1) is the ‘Design and evaluation of pan-CoV vaccines’. A comprehensive characterization of the B and T cell responses to vaccination will be carried out by Research Project 2 (RP2, ‘Immunological…
IRWIN M CHAIKEN · DREXEL UNIVERSITY · 2021 · $344,656 — SUMMARY HIV-1 is the causative agent of AIDS, which remains a global pandemic. The need continues for more effective and broadly active preventive strategies and anti-retroviral therapies to target infectious virus and already- infected cells. In both virus-cell and cell-to-cell infection, the metas…
Bidadi Venkataram Prasad · BAYLOR COLLEGE OF MEDICINE · 2021 · $653,816 — The long-term goal of our research is to understand the structural basis of the complex processes that regulate the replication cycle of rotaviruses (RVs), which are the global pathogens causing life-threatening infantile gastroenteritis. During 2013-2016, our studies have answered several questions…
Scott M Husson · TRIALTUS BIOSCIENCE, LLC · 2021 · $256,576 — Project Summary The goal of this STTR Phase I project is to demonstrate the feasibility of developing the first universal affinity membrane for the rapid, selective, one-step purification of difficult-to-purify proteins. Despite the urgency for expanding the application of gene editing systems and a…
Peter Palese · ROCKEFELLER UNIVERSITY · 2021 · $784,941 — Abstract Given the uncontrolled spread of SARS-CoV-2 and the devastating impact on public health, therapeutic interventions are urgently needed for disease control. Indeed, several biotech and academic groups are currently focusing their efforts on the isolation and clinical development of monoclona…
Jeniffer Bertha Hernandez · KECK GRADUATE INST OF APPLIED LIFE SCIS · 2021 · $1,851,627 — ABSTRACT One of the “holy grails” in immunology is to be able to directly predict tight-binding variable chain antibody sequences in silico against foreign or non-self `antigenic' proteins. Immunoglobulin chain rearrangement can potentially encode approximately 1016 different variants of antibody he…
JUN WANG · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $254,250 — Project Summary The rapid spread of SARS-CoV-2 and the resulting Coronavirus Disease 2019 (COVID-19) pose a global pandemic. SARS-CoV-2 and its family members share some puzzling, unique pathological features, most notably acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), …
LISA A JACKSON · KAISER FOUNDATION RESEARCH INSTITUTE · 2021 · $2,014,564 — This Supplemental Funding application requests funding for the Kaiser Washington Vaccine and Treatment Evaluation Unit (VTEU) to function as a clinical site for DMID study 21-0012, a Phase 1/2 study of delayed heterologous SARS-CoV-2 vaccine dosing (boost) after receipt of EUA vaccines. This clinica…
Dan H. Barouch · FRED HUTCHINSON CANCER RESEARCH CENTER · 2021 · $61,429,109 — FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the …
Kimberly Frances Raab-Graham · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2021 · $88,123 — PROJECT SUMMARY Overview: The project focuses on understanding the molecular basis of how disrupted calcium homeostasis leads to disrupted hippocampal network activity that results in maladaptive responses in neurons with TSC deficient signaling. Approximately 33% of children who have autism spectru…
David Huw Davies · UNIVERSITY OF CALIFORNIA-IRVINE · 2021 · $610,134 — PROJECT SUMMARY/ABSTRACT In this proposal we will define molecular and cellular mechanisms of different combinations of known adjuvant components MPLA (a TL4 agonist), CpG (a TLR9 agonist), agonists of cGAS-STING and NOD1/2 pathways, and a squalene-in-water emulsion (AddaVAX™). Our overall Aim is to…
Christian W. Mandl · TIBA BIOTECH, LLC · 2021 · $278,957 — Project Summary/Abstract (30 lines) The proposal is to develop an RNA-based multi-antigen SARS-CoV-2 vaccine, supporting NIAID’s call to develop a vaccine using emerging antigen design strategies and novel delivery approaches. The SARS-CoV-2 pandemic is actively threatening public health, world econ…
Kenneth C Bagley · ORLANCE, INC. · 2021 · $955,395 — ABSTRACT In response to the emerging COVID-19 (SARS-CoV-2) pandemic, this supplement proposal to R44 AI138733- 01 will leverage our cutting-edge nucleic acid vaccine strategies, some of which that were developed under this parent grant. Here, we request supplement funding to develop candidate COVID-…
Rajesh Khanna · REGULONIX, LLC · 2021 · $419,470 — ABSTRACT Revisions noted in blue font First reported in December of 2019, coronavirus disease (COVID-19) has taken the world by storm, exacting a heavy toll not only in terms of the number of deaths (~1,700,000) it has caused worldwide but also its decimation of world economies (~$8.8 trillion). Bec…
Curtis Layton · PROTILLION BIOSCIENCES, INC. · 2021 · $855,260 — Abstract Monoclonal antibodies and antibody fragments are an important class of therapeutics comprising a $150B industry. However, methods for discovering and optimizing antibodies to have desired affinity are generally laborious laboratory procedures that require months of hands-on research perform…